Sign In
Buy SGPYY
$42.52
+0.0600 (+0.141%)
At Close: Jun 23, 2026
LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
LOS ANGELES, CA / ACCESSWIRE / May 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
Sage's Net-Zero Target Receive SBTi Validation
09:00am, Wednesday, 22'nd May 2024
FTSE 100 tech company also receives A- rating from the Carbon Disclosure Project FTSE 100 tech company also receives A- rating from the Carbon Disclosure Project
Notes from the Desk: All Aboard the MBS Train
11:51am, Monday, 20'th May 2024
The agency MBS sector has emerged as one of the best relative valuation opportunities in the fixed income market over the past year. Given the stabilization in yields after the May FOMC meeting and th
Panagora Asset Management Inc. Purchases 311,483 Shares of Sabre Co. (NASDAQ:SABR)
07:16am, Monday, 20'th May 2024
Panagora Asset Management Inc. lifted its position in shares of Sabre Co. (NASDAQ:SABR – Free Report) by 66.9% during the fourth quarter, according to the company in its most recent filing with
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGE
09:01pm, Thursday, 16'th May 2024
NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
The Sage Group plc (SGGEF) Q2 2024 Earnings Call Transcript
11:31am, Thursday, 16'th May 2024
The Sage Group plc (OTCPK:SGGEF) Q2 2024 Earnings Conference Call May 16, 2024 3:30 AM ET Corporate Participants Steve Hare - Chief Executive Officer Jonathan Howell - Chief Financial Officer Conferen
Sage Group tumbles as growth was good but not good enough for the City
03:47am, Thursday, 16'th May 2024
First-half numbers from The Sage Group PLC (LSE:SGE) were good but not quite good enough for the City, sending the shares down over 10% to 1,070p. The stock had risen almost 50% over the past year and
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE)
Sage Group share price analysis: overvalued ahead of earnings
07:21am, Wednesday, 15'th May 2024
Sage Group (LON: SGE) share price has crawled back in the past few weeks as investors wait for its half-year financial results. After soaring to a record high of 1,285p in March, it entered a correcti
